Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer

Massimo Cristofanilli • 20 Oct 2018
ESMO 2018
Breast Cancer Fulvestrant Palbociclib
PALOMA-3

Massimo Cristofanilli, MD, from Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the PALOMA-3 study (NCT01942135) of palbociclib combined with fulvestrant for HR-/HER+ metastatic disease after endocrine failure. This video was recorded at the breast cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, which presented the latest updates for three major Phase III clinical trials.

More from Massimo Cristofanilli

Highlights of ISLB 2022
1:37
Highlights of ISLB 2022
Massimo Cristofanilli • 31 Oct 2022
Developments in liquid biopsy for breast cancer over 10 years
3:40
Developments in liquid biopsy for breast cancer over 10 years
Massimo Cristofanilli • 31 Oct 2022
The role of circulating tumor cell clusters in advanced disease
3:07
The role of circulating tumor cell clusters in advanced disease
Massimo Cristofanilli • 31 Oct 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals